{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:48:22Z","timestamp":1770277702831,"version":"3.49.0"},"reference-count":70,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.4125","type":"journal-article","created":{"date-parts":[[2015,5,31]],"date-time":"2015-05-31T18:06:00Z","timestamp":1433095560000},"page":"1323-1328","source":"Crossref","is-referenced-by-count":27,"title":["Autoimmune Hepatitis: Recent Advances in the Pathogenesis and New Diagnostic Guidelines in Japan"],"prefix":"10.2169","volume":"54","author":[{"given":"Hiromasa","family":"Ohira","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumichi","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol 27: 147-163, 2009.","DOI":"10.1146\/annurev.immunol.021908.132629"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun 34: 7-14, 2010.","DOI":"10.1016\/j.jaut.2009.08.010"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol 1: 113-128, 2007.","DOI":"10.1586\/17474124.1.1.113"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Abe M, Mashiba T, Zeniya M, Yamamoto K, Onji M, Tsubouchi H; Autoimmune Hepatitis Study Group-Subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol 46: 1136-1141, 2011.","DOI":"10.1007\/s00535-011-0421-y"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Onji M, Nonaka T, Horiike N, Moriwaki H, Muto Y, Ohta Y. Present status of autoimmune hepatitis in Japan. Gastroenterol Jpn 28: 134-138, 1993.","DOI":"10.1007\/BF02782906"},{"key":"6","unstructured":"6. Toda G, Zeniya M, Watanabe F, et al. Present status of autoimmune hepatitis in Japan: correlating the characteristics with international criteria in an area with a high rate of HCV infection. J Hepatol 26: 1207-1212, 1997."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Krawitt EL. Autoimmune hepatitis. N Engl J Med 354: 54-66, 2006.","DOI":"10.1056\/NEJMra050408"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Zachou K, Muratori P, Koukoulis GK, et al. Review article: autoimmune hepatitis: current management and challenges. Aliment Pharmacol Ther 38: 887-913, 2013.","DOI":"10.1111\/apt.12470"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Onji M, Zeniya M, Yamamoto K, Tsubouchi H. Autoimmune hepatitis: diagnosis and treatment guide in Japan, 2013. Hepatol Res 44: 368-370, 2014.","DOI":"10.1111\/hepr.12300"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zeniya M. Diagnosis of autoimmune hepatitis. In: Autoimmune Liver Diseases-perspectives from Japan. Ohira H, Ed. Springer Japan, Tokyo, 2014: 67-81.","DOI":"10.1007\/978-4-431-54789-1_5"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Miyake Y. Treatment of autoimmune hepatitis. In: Autoimmune Liver Diseases-perspectives from Japan. Ohira H, Ed. Springer Japan, Tokyo, 2014: 95-106.","DOI":"10.1007\/978-4-431-54789-1_7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem 40: 127-164, 2005.","DOI":"10.1016\/S0065-2423(05)40004-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Liberal R, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: a comprehensive review. J Autoimmun 41: 126-139, 2013.","DOI":"10.1016\/j.jaut.2012.11.002"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Takahashi H. Pathogenesis of autoimmune hepatitis. In: Autoimmune Liver Diseases-perspectives from Japan. Ohira H, Ed. Springer Japan, Tokyo, 2014: 3-20.","DOI":"10.1007\/978-4-431-54789-1_1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 139: 58-72, 2010.","DOI":"10.1053\/j.gastro.2010.04.053"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Seki T, Ota M, Furuta S, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 103: 1041-1047, 1992.","DOI":"10.1016\/0016-5085(92)90041-V"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 25: 317-323, 1997.","DOI":"10.1002\/hep.510250211"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Zeniya M, Takahashi H. Characteristics of autoimmune hepatitis in the Asia-Pacific Region: historical review. Hepatol Int 6: 342-349, 2012.","DOI":"10.1007\/s12072-011-9313-8"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Umemura T, Katsuyama Y, Yoshizawa K, et al. Human leukocyte antigen class II haplotypes affect clinical characteristics and progression of type 1 autoimmune hepatitis in Japan. PLoS One 9: e100565, 2014.","DOI":"10.1371\/journal.pone.0100565"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 31: 49-53, 2000.","DOI":"10.1002\/hep.510310110"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Miyake Y, Ikeda F, Takaki A, Nouso K, Yamamoto K. +49A\/G polymorphism of cytotoxic T-lymphocyte antigen 4 gene in type 1 autoimmune hepatitis and primary biliary cirrhosis: a meta-analysis. Hepatol Res 41: 151-159, 2011.","DOI":"10.1111\/j.1872-034X.2010.00757.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Hiraide A, Imazeki F, Yokosuka O, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol 100: 1322-1329, 2005.","DOI":"10.1111\/j.1572-0241.2005.41053.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 35: 126-131, 2002.","DOI":"10.1053\/jhep.2002.30084"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. de Boer YS, van Gerven NM, Zwiers A, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 147: 443-452, 2014.","DOI":"10.1053\/j.gastro.2014.04.022"},{"key":"25","unstructured":"25. Shantha S, Thyagarajan SP, Premavathy RK, et al. Correlation of autoimmune reactivity with hepatitis B and C virus (HBV and HCV) infection in histologically proven chronic liver diseases. Indian J Med Microbiol 20: 12-15, 2002."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Vento S, Cainelli F. Is there a role for viruses in triggering autoimmune hepatitis? Autoimmun Rev 3: 61-69, 2004.","DOI":"10.1016\/S1568-9972(03)00053-3"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Tanaka H, Tujioka H, Ueda H, et al. Autoimmune hepatitis triggered by acute hepatitis A. World J Gastroenterol 11: 6069-6071, 2005.","DOI":"10.3748\/wjg.v11.i38.6069"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Alla V, Abraham J, Siddiqui J, et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 40: 757-761, 2006.","DOI":"10.1097\/00004836-200609000-00018"},{"key":"29","unstructured":"29. Bj&ouml;rnsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 51: 2040-2048, 2010."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48: 322-335, 2008.","DOI":"10.1002\/hep.22306"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Szabo G, Dolganiuc A, Mandrekar P. Pattern recognition receptors: acontemporary view on liver diseases. Hepatology 44: 287-298, 2006.","DOI":"10.1002\/hep.21308"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Wu J, Meng Z, Jiang M, et al. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology 129: 363-374, 2010.","DOI":"10.1111\/j.1365-2567.2009.03179.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications or common illnesses. J Allergy Clin Immunol 124: 1141-1149, 2009.","DOI":"10.1016\/j.jaci.2009.11.016"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Autoimmun Rev 2: 241-247, 2003.","DOI":"10.1016\/S1568-9972(03)00017-X"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Oo YH, Hubscher SG, Adams DH. Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol Int 4: 475-493, 2010.","DOI":"10.1007\/s12072-010-9183-5"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Adaptive immunity in autoimmune hepatitis. Dig Dis 28: 63-69, 2010.","DOI":"10.1159\/000282066"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4<sup>+<\/sup>CD25<sup>+<\/sup> regulatory T-cells in autoimmune liver disease. J Hepatol 41: 31-37, 2004.","DOI":"10.1016\/j.jhep.2004.03.008"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4<sup>+<\/sup>CD25<sup>+<\/sup> regulatory T cells in health and autoimmune hepatitis. J Immunol 176: 4484-4491, 2006.","DOI":"10.4049\/jimmunol.176.7.4484"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Peiseler M, Sebode M, Franke B, et al. FOXP3<sup>+<\/sup> regulatory T cells in autoimmune hepatitis are fully functional and not reduced infrequency. J Hepatol 57: 125-132, 2012.","DOI":"10.1016\/j.jhep.2012.02.029"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Yu H, Huang J, Liu Y, et al. IL-17 contributes to autoimmune hepatitis. J Huazhong Univ Sci Technolog Med Sci 30: 443-446, 2010.","DOI":"10.1007\/s11596-010-0446-0"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Zhao L, Tang Y, You Z, et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One 6: e18909, 2011.","DOI":"10.1371\/journal.pone.0018909"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Zhao L, Qiu de K, Ma X. Th17 cells: the emerging reciprocal partner of regulatory T cells in the liver. J Dig Dis 11: 126-133, 2010.","DOI":"10.1111\/j.1751-2980.2010.00428.x"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Longhi MS, Liberal R, Holder B, et al. Inhibition of interleukin-17 promotes differentiation of CD25<sup>-<\/sup> cells into stable T regulatory cells in patients with autoimmune hepatitis. Gastroenterology 142: 1526-1535, 2012.","DOI":"10.1053\/j.gastro.2012.02.041"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Kido M, Watanabe N, Okazaki T, et al. Fatal autoimmune hepatitis induced by concurrent loss of naturallyarising regulatory T cells and PD-1-mediated signaling. Gastroenterology 135: 1333-1343, 2008.","DOI":"10.1053\/j.gastro.2008.06.042"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Aoki N, Kido M, Iwamoto S, et al. Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice. Gastroenterology 140: 1322-1333, 2011.","DOI":"10.1053\/j.gastro.2011.01.002"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Ikeda A, Aoki N, Kido M, et al. Progression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice. Hepatology 60: 224-236, 2014.","DOI":"10.1002\/hep.27087"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Maruoka R, Aoki N, Kido M, et al. Splenectomy prolongs the effects of corticosteroids in mouse models of autoimmune hepatitis. Gastroenterology 145: 209-220, 2013.","DOI":"10.1053\/j.gastro.2013.03.011"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Xu YT, Liu DJ, Meng FY, Li GB, Liu J. Possible benefit of splenectomy in liver transplantation for autoimmune hepatitis. Hepatobiliary Pancreat Dis Int 13: 328-331, 2014.","DOI":"10.1016\/S1499-3872(14)60256-3"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Alzarez R, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31: 929-938, 1999.","DOI":"10.1016\/S0168-8278(99)80297-9"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48: 169-176, 2008.","DOI":"10.1002\/hep.22322"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Ohira H, Takahashi A. Current trends in the diagnosis and treatment of autoimmune hepatitis in Japan. Hepatol Res 42: 131-138, 2012.","DOI":"10.1111\/j.1872-034X.2011.00904.x"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Onji M; The Autoimmune Hepatitis Study Group. Proposal of autoimmune hepatitis presenting with acute hepatitis, severe hepatitis and acute liver failure. Hepatol Res 41: 497, 2011.","DOI":"10.1111\/j.1872-034X.2011.00810.x"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Takahashi H, Zeniya M. Acute presentation of autoimmune hepatitis: does it exist? A published work review. Hepatol Res 41: 498-504, 2011.","DOI":"10.1111\/j.1872-034X.2011.00808.x"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Abe M, Onji M, Kawai-Ninomiya K, et al. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin Gastroenterol Hepatol 5: 255-258, 2007.","DOI":"10.1016\/j.cgh.2006.10.011"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. J Gastroenterol 43: 951-958, 2008.","DOI":"10.1007\/s00535-008-2254-x"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Miyake Y, Iwasaki Y, Kobashi H, et al. Autoimmune hepatitis with acute presentation in Japan. Dig Liver Dis 42: 51-54, 2010.","DOI":"10.1016\/j.dld.2009.04.009"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Ozaslan E, Efe C, Purnak T. Acute autoimmune hepatitis. Hepatol Res 41: 1015, 2011.","DOI":"10.1111\/j.1872-034X.2011.00861.x"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Fujiwara K, Yasui S, Yokosuka O. Efforts for making the diagnosis of acute onset autoimmune hepatitis. Hepatology 51: 371-372, 2011.","DOI":"10.1002\/hep.24331"},{"key":"59","unstructured":"59. Chr&eacute;tien P, Chousterman M, Abd Alsamad I, et al. Non-organ-specific autoantibodies in chronic hepatitis C patients: association with histological activity and fibrosis. J Autoimmun 32: 201-205, 2009."},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Toda G, Zeniya M, Watanabe F, et al. Present status of autoimmune hepatitis in Japan: correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hepatol 26: 1207-1212, 1997.","DOI":"10.1016\/S0168-8278(97)80453-9"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Marceau G, Lapierre P, B&eacute;land K, et al. LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? Hepatology 42: 675-668, 2005.","DOI":"10.1002\/hep.20816"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 125: 588-598, 1996.","DOI":"10.7326\/0003-4819-125-7-199610010-00009"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Badiani RG, Becker V, Perez RM, et al. Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis? World J Gastroenterol 16: 3704-3708, 2010.","DOI":"10.3748\/wjg.v16.i29.3704"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 51: 2193-2213, 2010.","DOI":"10.1002\/hep.23584"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Montano-Loza AJ, Carpenter HA, Czaja AJ, et al. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 27: 507-515, 2007.","DOI":"10.1111\/j.1478-3231.2007.01444.x"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Matsumoto K, Miyake Y, Matsushita H, et al. Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis. J Gastroenterol Hepatol 29: 110-115, 2014.","DOI":"10.1111\/jgh.12340"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Yokokawa J, Kanno Y, Abe K, et al. Anti-nucleosome autoantibodies as markers for autoimmune hepatitis and their correlation with disease activity. Hepatol Res 44: 420-428, 2014.","DOI":"10.1111\/hepr.12130"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Kanno Y, Watanabe H, Takahashi A, et al. Anti-phosphoenolpyruvate carboxykinase 2 antibody in patients with autoimmune hepatitis. Hepatol Res 44: 1019-1025, 2014.","DOI":"10.1111\/hepr.12276"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Miyake Y, Yamamoto K, Matsushita H, et al. Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1 autoimmune hepatitis. Hepatol Res 44: 1299-1307, 2014.","DOI":"10.1111\/hepr.12305"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Yamagiwa S, Kamimura H, Takamura M, et al. Presence of antibodies against self human leukocyte antigen class II molecules in autoimmune hepatitis. Int J Med Sci 11: 850-856, 2014.","DOI":"10.7150\/ijms.8633"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,8,25]],"date-time":"2019-08-25T18:00:22Z","timestamp":1566756022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/11\/54_54.4125\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.4125","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}